Multiple System Atrophy
147
39
52
59
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
17 trials with published results (12%)
Research Maturity
59 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.2%
12 terminated out of 147 trials
83.1%
-3.4% vs benchmark
6%
9 trials in Phase 3/4
29%
17 of 59 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 59 completed trials
Clinical Trials (147)
Post-Trial Access to ATH434 for Patients With Multiple System Atrophy
A Study of Lu AF82422 in Participants With Multiple System Atrophy
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
Clinical Laboratory Evaluation of Chronic Autonomic Failure
Expansion Study of ALT001 in Patients With Multiple System Atrophy
[18F]F-DOPA Imaging in Patients With Autonomic Failure
UB-312 in Patients With Synucleinopathies
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
Community Outreach for Palliative Engagement -- Parkinson Disease
Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
Synaptic Loss in Multiple System Atrophy
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers